Funding shortfall
The company has no sales and must finance development through equity, debt, or partnerships.
- Scope
- Operations, clinical trials, and commercialization readiness
- Materiality
- high
Kairos Pharma, LTD.
Kairos Pharma, Ltd. is a U.S.-based clinical-stage pharmaceutical company focused on acquiring, licensing, and developing drug candidates and related intellectual property. The company has no approved products or product sales yet, and its current business is centered on preclinical and clinical development, IP portfolio building, and capital raising to fund operations.
27.07
27.07
| % | |
|---|---|
| Licensed therapeutic programs | 0% Exclusive license rights to patented technologies and drug-development programs sourced from Cedars. |
| Preclinical development | 45% Early-stage research, candidate selection, and nonclinical studies to advance product concepts. |
| Clinical development | 35% Human clinical studies and related regulatory preparation for product candidates. |
| Intellectual property and business development | 20% Patent portfolio management, licensing, and partnering activities that support commercialization. |
Kairos Pharma does not yet sell approved products, so its near-term counterparties are not traditional end customers...
- Equity investorsprimary
Provide capital through IPO, PIPE, ELOC, and private financings because the company has no product revenue.
- Technology licensorsprimary
Supply exclusive patent rights and know-how, including Cedars-licensed programs that underpin the pipeline.
- Strategic advisors and consultantssecondary
Support corporate strategy, investor relations, valuation, and financing execution.
- Potential pharmaceutical partnerssecondary
May license or co-develop programs to help fund development and future commercialization.
- Future healthcare end usersemerging
Hospitals, physicians, and patients would be the ultimate users if candidates are approved.
Kairos Pharma is headquartered in the United States and its current operating footprint is primarily U.S...
- •Headquartered in the United States
- •Operations are centered on U.S. clinical and corporate activities
- •Uses Canadian advisory services for investor communications
- •Uses Puerto Rico-based consulting for capital markets support
- •No disclosed country revenue because product sales have not started
Kairos Pharma’s strategy is to advance licensed therapeutic programs through preclinical and clinical development while...
01
Advance pipeline programsmedium-term
Clinical progress is the main value driver for a company with no product sales.
02
Secure fundingshort-term
The company needs external capital to fund operations until any product revenue exists.
03
Pursue partnering and licensingmedium-term
Collaborations can provide cash, validation, and commercialization reach without full internal buildout.
04
Strengthen market positioningshort-term
Investor communications and corporate strategy support access to capital and deal flow.
Kairos Pharma is exposed to the core risks of a clinical-stage biotech: it may never obtain regulatory approval, may...
Clinical and regulatory failure
Drug candidates may not demonstrate safety or efficacy, or may not obtain approval.
- Scope
- Pipeline programs and future revenue potential
- Materiality
- high
Shareholder dilution
Recent and future financings, including PIPEs and ELOC usage, can expand share count materially.
- Scope
- Existing common stockholders
- Materiality
- high
Going-concern pressure
Persistent losses and negative operating cash flow increase the risk of liquidity stress.
- Scope
- Balance sheet and operating continuity
- Materiality
- high
Dependence on licensors and third parties
The company relies on licensed IP, advisors, and outside service providers to progress programs.
- Scope
- Program continuity and deal terms
- Materiality
- medium
Revenue recognition
Any future collaboration or license revenue may be recognized over time or at milestones depending on contract terms
Stock-based compensation
Can materially increase G&A expense without cash outflow
Warrants and equity financing costs
Affects dilution, financing expense, and potentially fair value measurements
Going-concern and liquidity estimates
Management judgment affects disclosures and assessment of funding sufficiency
Keros Therapeutics, Inc.
KROS · Pharmaceutical Preparations
Keros Therapeutics is a clinical-stage biopharmaceutical company developing protein therapeutics for disorders driven by dysfunctional TGF-β family signaling.
Kalaris Therapeutics, Inc.
KLRS · Biological Products, (No Diagnostic Substances)
Xeris Biopharma Holdings, Inc.
XERS · Pharmaceutical Preparations
Karyopharm Therapeutics Inc.
KPTI · Pharmaceutical Preparations
Camurus
CAMX.ST · Health Care
Camurus is an international biopharmaceutical company headquartered in Lund, Sweden, focused on developing and commercializing innovative long-acting medicines for severe and chronic diseases.
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
: 28.4.2026